Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice

Toxoplasmosis is a prevalent zoonotic parasitic disease caused by Toxoplasma gondii , which infects nearly all warm-blooded animals including humans. It causes substantial economic losses to the livestock industry and poses a considerable threat to public health. Currently, therapeutic options for toxoplasmosis remain highly limited, and no safe and effective vaccine is widely licensed for human use. In this study, we developed a LNP encapsulated mRNA vaccine encoding SRS34A, a surface localized protein highly expressed across developmental stages of T. gondii . ICR mice ( n = 5 per group) were intramuscularly immunized three times at a dose of 10 μg per mouse with the SRS34A-mRNA-LNP vaccine. Vaccination elicited a balanced Th1/Th2 immune response, as evidenced by high SRS34A-specific IgG titers and significantly elevated levels of both Th1-type cytokines (IL-12, TNF-α, IFN-γ) and the Th2-type cytokine IL-4. Challenge assays showed that vaccination conferred partial protection against T. gondii infection. In the chronic infection model with 100 type II ME49 tachyzoites (i.p.), vaccinated mice achieved an 80% survival rate versus 60% in controls, although the survival difference was not statistically significant. Meanwhile, both the number of brain cysts in vaccinated mice were significantly reduced compared with controls. For acute infection with the virulent type I RH strain, vaccination significantly prolonged mouse survival at a challenge dose of 100 tachyzoites (i.p.), and markedly reduced peritoneal parasite burden in a separate experiment with 10 5 RH tachyzoites. In conclusion, the SRS34A-mRNA-LNP vaccine effectively induces SRS34A-specific humoral immunity and a balanced Th1/Th2 cytokine response, and confers partial protection against both acute and chronic T. gondii infection in mice. These findings support SRS34A as a promising candidate for further development of mRNA vaccines against toxoplasmosis.

Authors

Institutions

Publication Details

Journal
Frontiers in Microbiology
Published
2026-11-19
DOI
https://doi.org/10.3389/fmicb.2026.1942102
Primary Topic
Toxoplasma gondii Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice

Jichao Yang, Xuke Yang, Senyang Li, Cuiqin Huang et al.
Frontiers in Microbiology
Toxoplasma gondii Research Studies
article

Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice

Jichao Yang, Xuke Yang, Senyang Li, Cuiqin Huang, Ruolin Dai, Weijie Zou, Xiangting Zhu, Junhong Lin, Xingcheng Lin, Guohua Qiu
article en

Abstract

Toxoplasmosis is a prevalent zoonotic parasitic disease caused by Toxoplasma gondii , which infects nearly all warm-blooded animals including humans. It causes substantial economic losses to the livestock industry and poses a considerable threat to public health. Currently, therapeutic options for toxoplasmosis remain highly limited, and no safe and effective vaccine is widely licensed for human use. In this study, we developed a LNP encapsulated mRNA vaccine encoding SRS34A, a surface localized protein highly expressed across developmental stages of T. gondii . ICR mice ( n = 5 per group) were intramuscularly immunized three times at a dose of 10 μg per mouse with the SRS34A-mRNA-LNP vaccine. Vaccination elicited a balanced Th1/Th2 immune response, as evidenced by high SRS34A-specific IgG titers and significantly elevated levels of both Th1-type cytokines (IL-12, TNF-α, IFN-γ) and the Th2-type cytokine IL-4. Challenge assays showed that vaccination conferred partial protection against T. gondii infection. In the chronic infection model with 100 type II ME49 tachyzoites (i.p.), vaccinated mice achieved an 80% survival rate versus 60% in controls, although the survival difference was not statistically significant. Meanwhile, both the number of brain cysts in vaccinated mice were significantly reduced compared with controls. For acute infection with the virulent type I RH strain, vaccination significantly prolonged mouse survival at a challenge dose of 100 tachyzoites (i.p.), and markedly reduced peritoneal parasite burden in a separate experiment with 10 5 RH tachyzoites. In conclusion, the SRS34A-mRNA-LNP vaccine effectively induces SRS34A-specific humoral immunity and a balanced Th1/Th2 cytokine response, and confers partial protection against both acute and chronic T. gondii infection in mice. These findings support SRS34A as a promising candidate for further development of mRNA vaccines against toxoplasmosis.

Frontiers in MicrobiologyVol. 17
Longyan University (CN), Anhui Medical University (CN), Henan Agricultural University (CN)
Toxoplasma gondii Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon